Selpercatinib
Other Protein Kinase Inhibitors
Sold as Retsevmo · RETEVMO
- Drug class
- Other Protein Kinase Inhibitors
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 13
Overview
Selpercatinib is an active pharmaceutical ingredient in the Other Protein Kinase Inhibitors group (L01EX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 8 | April 24, 2026 |
| EU European Union | EMA | 1 | February 12, 2026 |
| CA Canada | Health Canada | 4 | March 11, 2026 |
GBUnited Kingdom· MHRA
8 products
Uses
Retsevmo as monotherapy is indicated for the treatment of adults with: – advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with: – advanced RET fusion-positive thyroid cancer who are radioactive iodine- refractory (if radioactive iodine is appropriate) – advanced RET-mutant medullary thyroid cancer (MTC)
How to take
EUEuropean Union· EMA
1 product
Uses
1) Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with: – advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate) – advanced RET-mutant medullary thyroid cancer (MTC) 3
How to take
CACanada· Health Canada
4 products
4 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Drug interactions
Known interactions involving Selpercatinib. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 472. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL148950358 · revised April 24, 2026
- [2]European Medicines Agency · EMEA/H/C/005375 · revised February 12, 2026
- [3]Health Canada (DPD) · 02516918 · revised March 11, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.